Sanofi adds new inflammatory target to growing Nurix tie-up

Title

Sanofi Expands Collaboration with Nurix Therapeutics to Target Inflammation and Autoimmune Diseases

Keywords

• Sanofi
• Nurix Therapeutics
• Autoimmune diseases
• Inflammation
• STAT6 degrader
• Transcription factor
• Drug discovery
• Targeted protein degradation
• DEL-AI platform
• Licensing deal

Key Facts

- Collaboration Details:
Sanofi has paid $15 million in licensing fees to Nurix Therapeutics for an undisclosed drug program targeting a transcription factor involved in inflammation, distinct from the STAT6 degrader program2.

- STAT6 Program:
Nurix and Sanofi are also extending their partnership to develop STAT6 degraders, addressing type 2 inflammation by targeting the IL-4/IL-13 signaling pathways. A clinical candidate is expected to be nominated within a year1.

- Target Description:
The newly licensed target is a transcription factor serving as a central regulator of proinflammatory cytokines in autoimmune diseases26.

- DEL-AI Platform:
Nurix’s proprietary DEL-AI platform was used to derive drug candidates for previously undruggable targets, demonstrating innovation in targeted protein degradation67.

- Financial Implications:
To date, Sanofi has paid Nurix $105 million under their collaboration initiated in 2019 and remains eligible for up to $465 million in additional milestone payments, plus royalties27.

- Co-development Rights:
Nurix retains an option to co-develop and co-promote in the U.S., where profits and losses will be split, while earning royalties on international sales27.

- Broader Pipeline:
Nurix’s disclosed pipeline includes STAT6, IRAK4 degraders with Gilead, and NX-5948, alongside the new Sanofi collaboration programs targeting autoimmune and inflammatory diseases1.

Sources:

1. https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-extension-strategic-collaboration-0

2. https://www.stocktitan.net/news/NRIX/nurix-licenses-a-drug-discovery-program-to-sanofi-targeting-a-novel-b1do4y227ler.html

6. https://www.streetinsider.com/Corporate+News/Nurix+Therapeutics+(NRIX)+Licenses+a+Drug+Discovery+Program+to+Sanofi+Targeting+a+Novel+Transcription+Factor+for+Autoimmune+Diseases/24586589.html

7. https://www.thepharmaletter.com/nurix-expands-licensing-deal-with-sanofi